Kidney Week

Abstract: SA-PO0672

Preliminary Results of the Effect of SGLT2 Inhibitors on Renal Parameters of Patients with IgAN

Session Information

• Glomerular Diseases: Clinical, Outcomes, and Therapeutics Research - Other
  October 24, 2026 | Location: Exhibit Hall A, Convention Center
  Abstract Time: 10:00 AM - 12:00 PM

Category: Glomerular Diseases

• 1402 Glomerular Diseases: Clinical, Outcomes, and Therapeutics

Authors

• Gourdoupari, Eftychia Eirini Maria, Clinical and Interventional Nephrology Unit, Second Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens (NKUA), Attikon University Hospital, Athens, Greece

Eftychia Eirini Maria Gourdoupari, MD

• Koukoulaki, Maria, Department of Nephrology, Nikaia-Piraeus General Hospital “Agios Panteleimon”, Athens, Greece

Maria Koukoulaki, MD, PhD

• Gkika, Vasiliki, Clinical and Interventional Nephrology Unit, Second Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens (NKUA), Attikon University Hospital, Athens, Greece

Vasiliki Gkika, MD, MSc

• Pantzopoulou, Evangelia, Clinical and Interventional Nephrology Unit, Second Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens (NKUA), Attikon University Hospital, Athens, Greece

Evangelia Pantzopoulou, MD

• Chelioti, Eleni, Department of Nephrology, Tzaneio General Hospital of Piraeus, Athens, Greece

Eleni Chelioti, MD, PhD

• Chantzis, Ioannis, Department of Nephrology, Tzaneio General Hospital of Piraeus, Athens, Greece

Ioannis Chantzis, MD

• Tsaousi, Spyridoula S., Clinical and Interventional Nephrology Unit, Second Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens (NKUA), Attikon University Hospital, Athens, Greece

Spyridoula S. Tsaousi, MD

• Ainalidou, Lemonia, Department of Nephrology, Nikaia-Piraeus General Hospital “Agios Panteleimon”, Athens, Greece

Lemonia Ainalidou, MD, MSc

• Tsatsani, Georgia C., Department of Nephrology, Nikaia-Piraeus General Hospital “Agios Panteleimon”, Athens, Greece

Georgia C. Tsatsani, MD, DrMed

• Zermpala, Synodi, Department of Nephrology, Nikaia-Piraeus General Hospital “Agios Panteleimon”, Athens, Greece

Synodi Zermpala, DrMed

• Kalaitzidis, Rigas, Department of Nephrology, Nikaia-Piraeus General Hospital “Agios Panteleimon”, Athens, Greece

Rigas Kalaitzidis, MD

• Lionaki, Sophia, Clinical and Interventional Nephrology Unit, Second Department of Propaedeutic Internal Medicine, National and Kapodistrian University of Athens (NKUA), Attikon University Hospital, Athens, Greece

Sophia Lionaki, MD, PhD

Background

Aim: To investigate the effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on renal parameters in patients with IgA nephropathy (IgAN).

Methods

Included patients older than 16 years with histopathological confirmation of IgAN and were studied retrospectively. Demographics, comorbidities, clinical and laboratory findings at the time of diagnostic kidney biopsy and throughout follow-up, treatment regimens, and therapeutic responses were recorded. Clinical phenotypes of IgAN were categorized as follows: A) isolated microscopic hematuria, B) hematuria and proteinuria, and B) hematuria, proteinuria, and impaired renal function.

Results

Up to the present, 94 patients have been included in the study, with a median age of 48 years (IQR: 23). Fifty-six patients (60%) were males, 45 (48%) had arterial hypertension, and 10 (11%) had type 2 diabetes mellitus. Twenty two patients (32%) presented with isolated microscopic hematuria, 40 (57%) with hematuria and proteinuria, and 8 (11%) with hematuria, proteinuria, and impaired renal function. Seventy-seven patients (82%) were receiving renin–angiotensin–aldosterone system inhibitors (RAASi), while 52 (55%) had received immunosuppressive therapy. Overall, 31 patients (32.9%) were treated with SGLT2 inhibitors.
Patients receiving SGLT2i were more frequently males (p=0.001), were receiving RAASi at the time of SGLT2i initiation (p=0.004), and had significantly higher baseline 24-hour proteinuria at diagnosis compared with those who did not receive SGLT2i [2270 mg (IQR: 3500) vs. 910 mg (IQR: 1195), p=0.003]. Baseline mean eGFR in the overall cohort was 81 (± 45) mL/min/1.73 sqm, declining to 69 (± 47.5) mL/min/1.73 sqm after a median follow-up of 61 months (IQR: 122). Accordingly, the relative reduction in 24-hour proteinuria was greater in
the SGLT2i group [Δproteinuria: −601 mg (2578)] compared with patients who did not receive SGLT2i [Δproteinuria: −390 mg (110)] during the same period.

Conclusion

Based on our preliminary results, treatment with SGLT2 inhibitors appears to confer an additional beneficial effect on proteinuria reduction in patients with IgAN.